Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
birinapant + docetaxel
- Development stage
- Phase 2
- Lead developer
- Medivir
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Birinapant + docetaxel is a combination therapy consisting of birinapant, a small molecule SMAC (Second Mitochondria-derived Activator of Caspase) mimetic and antagonist of inhibitor of apoptosis proteins (IAPs), and docetaxel, a taxane-class chemotherapeutic agent. Birinapant sensitizes tumor cells to apoptosis by promoting degradation of cIAP1/2 and XIAP, thereby facilitating caspase activation and cell death, especially in the presence of tumor necrosis factor (TNF). Docetaxel induces apoptosis primarily by stabilizing microtubules and interfering with cell division, and it can also induce TNF production, further enhancing the pro-apoptotic effect of birinapant. This combination has shown synergistic antitumor activity in preclinical models of triple-negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC), including xenografts resistant to docetaxel monotherapy. Clinical trials have evaluated this combination for safety and efficacy in patients with advanced or metastatic solid tumors[1][2][4].
- Other names
- birinapant + docetaxel
02
Targets
BIRC7TUBB (Tubulin (alpha and beta subunits))XIAPBIRC2 (Cellular inhibitor of apoptosis protein 1)IAP (Inhibitor of apoptosis protein family)
Beyond the preview
Go deeper on birinapant + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on birinapant + docetaxel.